# Reps. Dina Titus and Ilhan Omar Introduce Higher Education Marijuana Research Act > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/academic-cannabis-research-funding-gap-act/ > **Published:** 2026-04-21T19:04:50-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:15:47-04:00 > **Clinical Summary:** Explore the academic cannabis research funding gap and how the Higher Education Marijuana Research Act aims to expand research capabilities. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Research PolicyClinical EvidenceFederal RegulationAcademic ResearchTherapeutics Why This Matters Federal research restrictions have severely limited high-quality clinical evidence for cannabis therapeutics, forcing clinicians to rely on observational data and patient reports. Enhanced academic research infrastructure could accelerate the development of standardized protocols and evidence-based dosing guidelines that clinicians desperately need. Clinical Summary The Higher Education Marijuana Research Act aims to expand [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) capabilities at universities by addressing federal regulatory barriers that currently limit academic institutions’ ability to conduct comprehensive cannabis studies. Current federal restrictions require researchers to use government-supplied cannabis of limited variety and quality, while also creating administrative burdens that discourage research participation. The legislation would facilitate access to diverse cannabis products that better reflect what patients actually use, potentially enabling more clinically relevant research on therapeutic applications, dosing, and safety profiles. Dr. Caplan’s Take “We’re practicing [evidence-based medicine](https://cedclinic.com/digital-health-expertise-modern-challenge/) with a critically thin evidence base. This legislation could finally give us the robust clinical data we need to move beyond educated guessing about optimal formulations, dosing, and patient selection for cannabis therapeutics.” Clinical Perspective 🧠 Clinicians should anticipate that expanded research may eventually provide clearer guidance on strain selection, cannabinoid ratios, and dosing protocols that currently rely heavily on patient experimentation. However, meaningful clinical applications from enhanced research will likely take years to materialize, so current evidence-based approaches using available data remain appropriate for patient care decisions. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Reps.%20Dina%20Titus%20and%20Ilhan%20Omar%20Introduce%20Higher%20Education%20Marijuana%20Research%20Ac...%20%40drcaplan&url=https%3A//www.quiverquant.com/news/Press%2BRelease%253A%2BReps.%2BDina%2BTitus%2Band%2BIlhan%2BOmar%2BIntroduce%2BHigher%2BEducation%2BMarijuana%2BResearch%2BAct)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.quiverquant.com/news/Press%2BRelease%253A%2BReps.%2BDina%2BTitus%2Band%2BIlhan%2BOmar%2BIntroduce%2BHigher%2BEducation%2BMarijuana%2BResearch%2BAct)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Reps.%20Dina%20Titus%20and%20Ilhan%20Omar%20Introduce%20Higher%20Education%20Marijuana%20Research%20Ac...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.quiverquant.com/news/Press%2BRelease%253A%2BReps.%2BDina%2BTitus%2Band%2BIlhan%2BOmar%2BIntroduce%2BHigher%2BEducation%2BMarijuana%2BResearch%2BAct)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.quiverquant.com/news/Press+Release%3A+Reps.+Dina+Titus+and+Ilhan+Omar+Introduce+Higher+Education+Marijuana+Research+Act](https://www.quiverquant.com/news/Press+Release%3A+Reps.+Dina+Titus+and+Ilhan+Omar+Introduce+Higher+Education+Marijuana+Research+Act) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating for this cannabis news?](#What_is_the_clinical_relevance_rating_for_this_cannabis_news) - [What type of cannabis-related content does this article cover?](#What_type_of_cannabis-related_content_does_this_article_cover) - [Why is this article marked as “New”?](#Why_is_this_article_marked_as_8220New8221) - [What does “Notable Clinical Interest” mean for healthcare providers?](#What_does_8220Notable_Clinical_Interest8221_mean_for_healthcare_providers) - [How does this relate to federal cannabis regulation?](#How_does_this_relate_to_federal_cannabis_regulation) - [Related](#Related) ## FAQ #### What is the clinical relevance rating for this cannabis news? This article has been assigned CED Clinical Relevance #70, which indicates “Notable Clinical Interest.” This rating suggests the content contains emerging findings or policy developments that healthcare professionals should monitor closely. #### What type of cannabis-related content does this article cover? Based on the tags, this article covers research policy, clinical evidence, federal regulation, and academic research related to cannabis. It appears to be a comprehensive piece addressing multiple aspects of cannabis in healthcare and policy contexts. #### Why is this article marked as “New”? The “New” designation indicates this is recently published content from CED Clinic. This helps healthcare professionals identify the most current information in the rapidly evolving field of [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) and policy. #### What does “Notable Clinical Interest” mean for healthcare providers? This classification suggests the article contains information that could impact clinical practice or patient care decisions. Healthcare providers should review this content as it may influence treatment protocols or regulatory compliance requirements. #### How does this relate to federal cannabis regulation? The federal regulation tag indicates this article discusses policy changes or developments at the national level. These federal updates are particularly important as they can override state-level cannabis laws and affect [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) accessibility and research funding. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [The Realities of Rescheduling Medical Cannabis | Rockefeller Institute of Government](https://cedclinic.com/the-realities-of-rescheduling-medical-cannabis-rockefeller-institute-of-government/) An in-depth look at the complexities and implications of rescheduling [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) at the federal level. [Read More](https://cedclinic.com/the-realities-of-rescheduling-medical-cannabis-rockefeller-institute-of-government/) [Medical marijuana reclassification could expand research, lower prices | FOX 10 Phoenix](https://cedclinic.com/medical-marijuana-reclassification-research-opportunities/) Explore how reclassification efforts may enhance research opportunities and affect market prices for [medical marijuana](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). [Learn More](https://cedclinic.com/medical-marijuana-reclassification-research-opportunities/) [Michigan universities can't study dispensary pot on campus. MSU went mobile](https://cedclinic.com/michigan-universities-cant-study-dispensary-pot-on-campus-msu-went-mobile/) A report on how Michigan State University adapted to federal restrictions by innovating [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) methods. [Discover How](https://cedclinic.com/michigan-universities-cant-study-dispensary-pot-on-campus-msu-went-mobile/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).